- Japanese patent issuances facilitate commercialization of MCC in
BELLEVILLE, ON, June 17 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC),
a research-based, technology-driven Canadian biopharmaceutical company,
today announced the issuance of a number of patents for its proprietary
Mycobacterial Cell Wall-DNA Complex (MCC) composition and its
Oligonucleotide technology platform.
The following is a list of the Bioniche MCC patent applications that
have been allowed or issued in the various international jurisdictions:
"Composition and Method for Regulating Cell Proliferation and Cell
Death" granted in Japan as Patent No. 4335435; and in Canada as Patent
"Composition and Method for the Treatment of Bladder Cancer" granted
in Japan as patent No. 4426067.
"Chemotherapeutic Composition and Method" granted in Japan as Patent
No. 4380922; and has been allowed in Canada.
"Method for the Treatment of Inflammation": A "Notice of Decision to
Grant a Patent" has been received for the Japanese application.
About Mycobacterial Cell Wall-DNA Complex (MCC)
Cell Wall-DNA Complex (MCC) is a patented cell wall composition isolated
from Mycobacterium phlei. MCC is a bifunctional agent with a direct
effect on cancer cells (chemotherapeutic-like activity) as well as a
stimulatory activity on immune effector cells such as macrophages and
monocytes. MCC is a platform technology, offering opportunities to
develop a range of oncology and immune stimulatory applications in both
humans and animals.
The following is a list of the Bioniche Oligonucleotide patent
applications that has been allowed or issued in the various
'Therapeutically Useful Synthetic Oligonucleotides' granted in Europe
as EP Patent No. 1867718 (validated in: Switzerland, Germany, Denmark,
Spain, France, Great Britain and Italy). This application has also
been granted in Israel as Patent No. 150196.
"Modulation of FAS and FASL Expression" issued in the US as Patent No.
"Oligonucleotide Compositions and Their Use to Induce Differentiation
of Cells" granted in Japan as Patent No. 4460220; and in South Korea
as Patent No. 913860.
"Conformation-Activity Relationship of Apoptosis-Inducing
Phosphodiester Oligonucleotides" granted in South Korea as Patent No.
943567; and a "Notice of Decision to Grant a Patent" has been received
for the Japanese application.
"Therapeutically Useful Triethyleneglycol Cholesteryl
Oligonucleotides" granted in Japan as Patent No. 4405259; and issued
in the U.S. as Patent No. 7635686.
"The development and maintenance of our patent portfolio is an important
investment for the Company," said Graeme McRae, Chairman, President &
CEO. "It ensures long-term protection of products in the marketplace
following successful registration."
About the Oligonucleotide Technology Platform
Bioniche announced the discovery of a new class of molecules with
potential anticancer activity, referred to by the Company under the
trademark, "Oligomodulator™". This new class of molecules
with potential clinical anticancer activity and immune modulating
properties is composed of short non-antisense DNA Oligonucleotides that
appear to possess a range of novel pharmacological activities. The
Company has continued to develop the Oligonucleotide technology platform
in the areas of immune stimulation and modulation.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc.
is a research-based, technology-driven Canadian biopharmaceutical
company focused on the discovery, development, manufacturing, and
marketing of proprietary products for human and animal health markets
worldwide. The fully-integrated company employs approximately 200
skilled personnel and has three operating divisions: Human Health,
Animal Health, and Food Safety. The Company's primary goal is to develop
proprietary cancer therapies supported by revenues from marketed
products in human and animal health. For more information, please visit www.Bioniche.com.
Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current
expectation regarding future events. These forward-looking statements
involve risk and uncertainties, which may cause, but are not limited to,
changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact
of competitive products and pricing, new product development,
uncertainties related to the regulatory approval process, and other
risks detailed from time to time in the Company's ongoing quarterly and
SOURCE Telesta Therapeutics Inc.
For further information: For further information:
Jennifer Shea, Vice-President, Communications, Investor & Government Relations
Bioniche Life Sciences Inc.
Telephone: (613) 966-8058
Cell: (613) 391-2097